Theratechnologies, Inc. (THTX) News
Filter THTX News Items
THTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest THTX News From Around the Web
Below are the latest news stories about THERATECHNOLOGIES INC that investors may wish to consider to help them evaluate THTX as an investment opportunity.
Open Letter to Shareholders from CEO Paul LevesqueTheratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key ObjectivesFY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidanceFY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash flow from operating activitiesFY2023 operating plan to focus on achieving positive EBITDA1 in the near-term based on commercial business growth and new asset opportunities |
Shareholders in Theratechnologies (TSE:TH) are in the red if they invested five years agoSome stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held... |
Theratechnologies Announces Update from Ongoing TH1902 StudyThis news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021.MONTREAL, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of p |
Theratechnologies Is An Underappreciated HIV-Focused Company, Analyst SaysCantor Fitzgerald has initiated coverage on Theratechnologies Inc (NASDAQ: THTX) with an Overweight rating and a price target of $9. Theratechnologies' two HIV drugs, Egrifta and Trogarzo, could grow 20% a year for the foreseeable future, the analyst writes. Being conservative, Cantor has modeled a mid-teens sales growth for these two products. Product innovations and dedicated sales focus on these two drugs have driven uptake. THTX's decision to internalize its field force and strengthen its co |
Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue MicroarraysPoster for presentation at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics enhances understanding of SORT1 expression in healthy and tumor tissuesExtensive dataset underscores potential of SORT1 as a new anticancer therapeutic target MONTREAL, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies re |
10 Best Low Price Pharma Stocks To Buy NowIn this article, we discuss 10 best low price pharma stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Low Price Pharma Stocks To Buy Now. The global pharmaceuticals market was forecasted to grow from $1454.66 billion in 2021 to $1587.05 billion in 2022 at a […] |
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update- Q3 2022 Consolidated Revenue Growth of 17% to $20.8 million - Q3 2022 North American Revenue Growth of 19% - TH1902 Phase 1 basket trial proceeding as planned - On track to meet FY2022 Revenue Guidance $79 - $82 million MONTREAL, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and finan |
Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR SymposiumMONTREAL, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of SORT1, the target for Theratechnologies’ oncology platform, in several cancer types. The data will be presented in a poster session at the 34th joint symposium of t |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGood morning, investor! |
Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced PopulationReduces maintenance dose from a 15-minute IV infusion to a 30-second, undiluted IV push every two weeksSafety profile of Trogarzo® IV push similar to that of IV infusionNew method of administration designed to make maintenance dosing easier for patients and health care providers and allow more clinics to administer treatment MONTREAL, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on th |